Presentations will include Results from the Phase III coBRIM study of Roche’s investigational MEK inhibitor cobimetinib plus Zelboraf compared to Zelboraf alone, potentially paving the way for a new standard of care Final survival data from the Phase III CLEOPATRA study of the combination of Perjeta, Herceptin and chemotherapy, further confirming the potential of this […]
The cobas 6800/8800 Systems offer advanced performance with next generation donor screening assays Basel, 2 September 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the commercial availability of the cobas 6800/8800 Systems, two integrated and fully automated molecular testing systems for blood and plasma donor screening in markets accepting the CE mark. The […]
Upon approval, RoACTEMRA would be the first IL-6 biologic available in subcutaneous and intravenous administration for both monotherapy and combination therapy New subcutaneous formulation would offer greater flexibility for rheumatoid arthritis patients Basel, 20 December 2013 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the subcutaneous formulation of RoACTEMRA (tocilizumab) has received a positive […]
Second stage of CLL11 study showed Gazyva plus chlorambucil significantly reduced the risk of disease worsening or death by 61% compared to MabThera/Rituxan plus chlorambucil for people with previously untreated chronic lymphocytic leukemia Updated data from Stage 1a of CLL11 showed Gazyva plus chlorambucil improved overall survival compared to chlorambucil alone Full CLL11 study results […]
Basel, 4 November 2013 – Roche licenses investigational antibiotic POL7080 from Polyphor. POL7080 targets Pseudomonas species with a novel mode of action. This “superbug” bacterium is commonly found in hospitals and has evolved to become resistant to many antibiotic treatments. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Polyphor Ltd., a privately held pharmaceutical company, announced today […]
Gazyva demonstrated an 84 percent reduction in the risk of disease worsening or death when combined with chemotherapy compared to chemotherapy alone Gazyva is the first medicine approved with the FDA’s Breakthrough Therapy Designation Basel, 1 November 2013 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved […]
TUCSON, Arizona and INGELHEIM, Germany, 19 September 2013 – Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, and Boehringer Ingelheim (BI) announced today that they have entered into an agreement to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim Oncology programmes. As part of the agreement, Ventana will utilize its […]